Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 11/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461843 | 0.85 | NR1H2 (0.59) | NR1H3NR1H2 | |
| SCHEMBL8198555 | 0.84 | NR1H3 (0.40) | NR1H3NR1H2HDAC1MAP4K4SUV39H2 | |
| SCHEMBL2463578 | 0.84 | NR1H3 (0.40) | NR1H3NR1H2HDAC1MAP4K4SUV39H2 | |
| SCHEMBL2458839 | 0.81 | NR1H2 (0.41) | NR1H3NR1H2HDAC1GPR119 | |
| SCHEMBL2458980 | 0.78 | MAPT (0.41) | NR1H3NR1H2HDAC1GPR119 | |
| SCHEMBL2461911 | 0.75 | IP6K1 (0.36) | HDAC1IP6K1 | |
| SCHEMBL2458971 | 0.74 | IP6K1 (0.38) | IP6K1 | |
| SCHEMBL2463468 | 0.74 | CTSK (0.41) | IP6K1 | |
| SCHEMBL2458826 | 0.73 | SIRT6 (0.41) | NR1H3NR1H2 | |
| SCHEMBL8198584 | 0.73 | SIRT6 (0.41) | NR1H3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| EP-2069315-A2 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. Organon (NL) | 2009-06-17 | — | — | EP | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| WO-2008033764-A2 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | NR1H3 2261/4885NR1H2 1739/4885HDAC1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.